Indication (pathologie):
Inflammatory bowel disease
Identifiant SNOMED-CT:
24526004
Etudes cliniques
-
Prevalence and risk factors of fatigue in IBD patientsRecrutement: Ouvert
-
A prospective study to evaluate the suture pattern with the Endomina suturing device for endoscopic sleeve gastroplasty (ESG)Indication (pathologie):ObesityIdentifiant SNOMED-CT:414916001Recrutement: Ouvert
-
A phase 2 study of INCMGA00012 in participants with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapyIndication (pathologie):Anal squamous cell carcinomaIdentifiant SNOMED-CT:255084004Phase de l'étude: Phase IIRecrutement: Ouvert
-
Effects of plasma exchange with human serum albumin 5% (PE-A 5%) on short-term survival in subjects with “acute-on-chronic liver failure” (ACLF) at high risk of hospital mortalityIndication (pathologie):Acute on chronic alcoholic liver diseaseIdentifiant SNOMED-CT:713370005Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A phase 1b open-label study assessing the pharmacokinetics, tolerability, and safety of oral trimetazidine in subjects with acute-on-chronic liver failure - trust: trimetazidine for acute on chronic liver failure studyIndication (pathologie):Acute on chronic alcoholic liver diseaseIdentifiant SNOMED-CT:713370005Phase de l'étude: Phase IRecrutement: Ouvert
-
REFINE: Regorafenib observational study in hepatocellular carcinomaIndication (pathologie):Hepatocellular carcinomaIdentifiant SNOMED-CT:109841003Phase de l'étude: Phase IVRecrutement: Ouvert
-
Cilostazol as imatinib synergiser in patients with unresectable or metastatic gist treated by GLIVEC®Indication (pathologie):Gastrointestinal stromal tumorIdentifiant SNOMED-CT:420120006Phase de l'étude: Phase IIRecrutement: Ouvert
-
Prodige 34-etude de phase 3 randomisée évaluant la chimiothérapie adjuvante après résection d’un adénocarcinome colique de stade 3 chez les patients de 70 ans et plus (adage)Indication (pathologie):AdenocarcinomaIdentifiant SNOMED-CT:443961001Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A phase 4, double-blind, randomized, placebo-controlled study evaluating the pharmacokinetics and safety of obeticholic acid in patients with primary biliary cholangitis and moderate to severe hepatic impairmentIndication (pathologie):Primary biliary cholangitisIdentifiant SNOMED-CT:31712002Phase de l'étude: Phase IVRecrutement: Ouvert
-
A first-time-in human (FTIH), Phase I, randomized,multi-centric, single-blind, controlled dose-escalation study to evaluate the reactogenicity, safety, immunogenicity and efficacy of GSK Biologicals’ HBV viral vector vaccines given in a prime-boost schedule with sequential or co-administration of adjuvanted proteins therapeutic vaccine (GSK3528869A) in chronic Hepatitis B patients (18-65 years old) well controlled under nucleo(s)tides analogues (NA) therapy.Indication (pathologie):Chronic type B viral hepatitisIdentifiant SNOMED-CT:61977001Phase de l'étude: Phase IRecrutement: Ouvert
-
Total Motorized Spiral Enteroscopy Trial (TMSET) (étude multicentrique européenne sur l’entéroscopie complète au moyen du nouvel endoscope motorisé à spirale)Indication (pathologie):EnteroscopyIdentifiant SNOMED-CT:235147008Recrutement: Ouvert
-
Prevention of mortality with long-term administration of human albumin in subjects with decompensated cirrhosis and ascitesIndication (pathologie):Decompensated cirrhosisIdentifiant SNOMED-CT:716203000Indication (pathologie):AscitesIdentifiant SNOMED-CT:389026000Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A phase 3, randomized, double-blind study of adjuvant nivolumab versus placebo for participants with hepatocellular carcinoma who are at high risk of recurrence after curative hepatic resection or ablationIndication (pathologie):Hepatocellular carcinomaIdentifiant SNOMED-CT:109841003Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A multicenter, randomized, double-blind, placebo-controlled induction study to evaluate the efficacy and safety of risankizumab in subjects with moderately to severely active ulcerative colitis who have failed prior biologic therapyIndication (pathologie):Ulcerative colitisIdentifiant SNOMED-CT:64766004Phase de l'étude: Phase IIIRecrutement: Ouvert
-
A multicenter, randomized, double-blind, placebo-controlled 52-week maintenance and an open-label extension study of the efficacy and safety of risankizumab in subjects with ulcerative colitis who responded to induction treatment in M16-067 or M16-065Indication (pathologie):Ulcerative colitisIdentifiant SNOMED-CT:64766004Phase de l'étude: Phase IIIRecrutement: Ouvert
-
Endomina-v2mini-eftr: a prospective study to evaluate the safety and feasibility of an endoluminal suturing device (Endomina-v2mini) as an aid for endoscopic full thickness resectionIndication (pathologie):Endoscopic mucosal biopsy and resection kitIdentifiant SNOMED-CT:714733006Indication (pathologie):Endoscopic submucosal dissection of rectum using colonoscopeIdentifiant SNOMED-CT:713154003Recrutement: Ouvert
-
Protocol endomina–v2mini-diverticulum: A prospective study to evaluate the safety and feasibility of an endoluminal-suturing device (Endomina-v2mini) as an aid for diverticulum treatmentIndication (pathologie):esophageal diverticulumIdentifiant SNOMED-CT:235637006Recrutement: Ouvert
-
A pilot study to evaluate the feasibility and the safety of an enoluminal-suturing device (endomina-v2 mini) as a treatment for GERDIndication (pathologie):Gastro-esophageal refluxIdentifiant SNOMED-CT:235595009Recrutement: Ouvert
-
A first-in-human, double-blind, randomized, placebo-controlled, Phase 1 study to evaluate the safety, tolerability, reactogenicity, and immunogenicity of JNJ-64300535, a DNA vaccine, administered by electroporation-mediated intramuscular injection, in participants with chronic Hepatitis B who are on stable nucleos(t)ide therapy and virologically suppressedIndication (pathologie):Chronic viral hepatitisIdentifiant SNOMED-CT:61977001Phase de l'étude: Phase IRecrutement: Ouvert
-
A two-part randomized, double-blind, placebo-controlled multicenter dose ranging and confirmatory study to assess the safety and efficacy of VAY736 in autoimmune hepatitis patients with incomplete response to or intolerance of standard therapy (AMBER)Indication (pathologie):Autoimmune hepatitisIdentifiant SNOMED-CT:408335007Phase de l'étude: Phase IIIRecrutement: Ouvert